Fatal Thrombocytopaenia Temporally Related to the Administration of Alemtuzumab (MabCampath) for Refractory CLL Despite Early Discontinuation of Therapy

Author： Haider Imran   Cahill Mary  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.9, Iss.5-6, 2004-10, pp. : 409-411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Induction therapy for adult small bowel transplant with Campath-1H

By Nishida S.   Levi D.   Kato T.   Madariaga J.   Nery J.   Tzakis A.  

Transplantation Proceedings, Vol. 34, Iss. 5, 2002-08 ,pp. : 1889-1891

Elsevier

Access to resources Recommend Favorite

Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides

By Kwong Yok-Lam  

Annals of Hematology, Vol. 93, Iss. 4, 2014-04 ,pp. : 713-714

Springer Publishing Company

Access to resources Recommend Favorite

A review of Campath in autoimmune disease: Biologic therapy in the gray zone between immunosuppression and immunoablation

By Reiff Andreas  

Hematology, Vol. 10, Iss. 2, 2005-04 ,pp. : 79-93

Maney Publishing

Access to resources Recommend Favorite

Rituximab Therapy for Refractory Idiopathic Scleritis

By Bogdanic-Werner Katherine   Fernandez-Sanz Guillermo   Alejandre Alba Nicolás   Ferrer Soldevila Patricia   Romero-Bueno Fredeswinda I.   Sanchez-Pernaute Olga  

Ocular Immunology and Inflammation, Vol. 21, Iss. 4, 2013-08 ,pp. : 329-332

Informa Healthcare

Access to resources Recommend Favorite

Prolongation of allograft survival by administration of mAb specific for the three subunits of IL-2 receptor

By Yasuda K.  

International Immunology, Vol. 10, Iss. 5, 1998-05 ,pp. : 561-567

Oxford University Press

Access to resources Recommend Favorite